Bevacizumab: a new way of doing business?

C Canning; A Lotery

doi:10.1038/sj.eye.6702501

Bevacizumab: a new way of doing business?

Eye (Lond). 2006 Sep;20(9):985-7. doi: 10.1038/sj.eye.6702501. Epub 2006 Jul 21.

Authors

C Canning¹, A Lotery

Affiliation

¹ Southampton Eye Unit, Southampton General Hospital, Southampton, UK.

PMID: 16858443
DOI: 10.1038/sj.eye.6702501

Abstract

This review highlights the history of the development of treatments for choroidal neovascularization (wct AMD). It examines how drug therapies have evolved for the management of age-related macular degeneration (AMD) and the value of randomised clinical trials in determining efficacy. Finally it examines the emerging practice of utilising bevacizumab for the treatment of choroidal neovascularization despite the lack of any phase III clinical trial data.

Publication types

Review

MeSH terms

Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Bevacizumab
Choroidal Neovascularization / drug therapy*
Humans
Macular Degeneration / drug therapy*
Randomized Controlled Trials as Topic
Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Vascular Endothelial Growth Factor A
Bevacizumab